Clinical characteristics and prognostic factors of pulmonary MALT lymphoma

European Respiratory Journal

Volumn 34, Issue 6, 2009, Pages 1408-1416

  Borie, R ^a,b,c   Wislez, M ^a,b   Thabut, G ^c   Antoine, M ^a   Rabbat, A ^d   Couderc, L J ^e,f   Monnet, I ^g   Nunes, H ^h,i   Blanc, F X ^j   Mal, H ^c   Bergeron, A ^k   Dusser, D ^l   Israel Biet D ^m   Crestani, B ^c   Cadranel, J ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BICHAT HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e FOCH HOSPITAL   (France)

^f University Paris Ile de France Ouest   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h AVICENNE HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS 13   (France)

^j BICÊTRE HOSPITAL   (France)

^k SAINT LOUIS HOSPITAL   (France)

^l Institut Cochin   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

Chorambucil; Mucosa associated lymphoid tissue derived lymphoma; Prognostic; Pulmonary lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNE DISEASE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; COUGHING; DYSPNEA; FEMALE; FEVER; GROUPS BY AGE; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG CARCINOMA; LUNG MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NIGHT SWEAT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT INFECTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 73249151812     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00039309     Document Type: Article

References (39)

1. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802-806.
2. Montalban C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosaassociated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 1995; 6: 355-362.
3. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101: 2489-2495.
4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
5. Isaacson P, Wright DH. Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 1984; 53: 2515-2524.
6. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997; 90: 766-775.
7. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 2006; 107: 3034-3044.
8. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577.
9. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-1630.
10. Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosaassociated lymphoid tissue. Ann Intern Med 1995; 122: 767-769.
11. Montalban C, Manzanal A, Boixeda D, et al. Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Ann Oncol 1997; 8: Suppl. 2, 37-39.
12. Savio A, Franzin G, Wotherspoon AC, et al. Diagnosis and posttreatment follow-up of Helicobacter pylori-positive gastric lymphoma ofmucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 1996; 87: 1255-1260.
13. Isaacson PG, Mü ller-Hermelink HK, Piris MA, et al. Extranodal marginal zone B-cell lymphoma of maucosa-associated lymphoid tissue (MALT lymphoma). In: Press I, Jaffe ES, Harris NL, et al., eds. Pathology and Genetics: Tumours of Haematopoietic Tissues. World Health Organization Classification of Tumours. Lyon, WHO, 2001; pp. 157-160.
14. Wislez M, Cadranel J, Antoine M, et al. Lymphoma of pulmonary mucosa-associated lymphoid tissue: CT scan findings and pathological correlations. Eur Respir J 1999; 14: 423-429.
15. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
16. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?Am J Respir Crit Care Med 2007; 176: 691-697.
17. Cordier JF, Chailleux E, Lauque D, et al. Primary pulmonary lymphomas. A clinical study of 70 cases in nonimmunocompromised patients. Chest 1993; 103: 201-208.
18. Bae YA, Lee KS, Han J, et al. Marginal zone B-cell lymphoma of bronchus-associated lymphoid tissue: imaging findings in 21 patients. Chest 2008; 133: 433-440.
19. Campo E, Chott A, Kinney MC, et al. Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology 2006; 48: 481-504.
20. de Boer JP, Hiddink RF, Raderer M, et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica 2008; 93: 201-206.
21. 18F-Fluoro- deoxyglucose positron emission tomography in lymphoma of mucosaassociated lymphoid tissue: histology makes the difference. Ann Oncol 2006; 17: 1761-1765.
22. Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging 2008; 35: 1424-1430.
23. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978; 89: 888-892.
24. Ekstrom Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111: 4029-4038.
25. Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002; 20: 4255-4260.
26. Katzenstein AL, Peiper SC. Detection of Epstein-Barr virus genomes in lymphomatoid granulomatosis: analysis of 29 cases by the polymerase chain reaction technique. Mod Pathol 1990; 3: 435-441.
27. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. J Clin Oncol 2005; 23: 4372-4380.
28. Hansen JM, Wildner-Christensen M, Hallas J, et al. Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. Am J Gastroenterol 2008; 103: 1106-1113.
29. Chan WY, Chan EK, Chow JH. Epstein-Barr virus-associated gastric lymphomas are distinct from mucosa-associated lymphoid tissue-type lymphomas: genetic abnormalities of p53 gene. Diagn Mol Pathol 2001; 10: 153-160.
30. Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Non-gastric extra-nodal marginal zone lymphomas - a single centre experience on 76 patients. Leuk Lymphoma 2008; 49: 2308-2315.
31. Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol 2008; 19: Suppl. 4, iv70-iv73.
32. Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006; 11: 285-291.
33. Pinotti G, Zucca E, Roggero E, et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997; 26: 527-537.
34. Thieblemont C, Dumontet C, Bouafia F, et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk Lymphoma 2003; 44: 257-262.
35. Zucca E, Dreyling M. Gastric marginal zone lymphoma of MALT type: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: Suppl. 2, ii70-ii71.
36. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as firstline and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-4267.
37. Coiffier B, Thieblemont C, Felman P, et al. Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. Semin Hematol 1999; 36: 198-208.
38. Troch M, Streubel B, Petkov V, et al. Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res 2007; 27: 3633-3637.
39. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 2000; 156: 1183-1188.